^
    1d
    Comparative Retrospective Analysis of Immunotherapy Combined with Anti-Angiogenic Agents and Nab-Paclitaxel in Metastatic Gastroesophageal Junction Adenocarcinoma. (PubMed, Int J Gen Med)
    Patients were divided into two groups: the observation group (sintilimab + apatinib + albumin-bound paclitaxel, n = 42) and the control group (apatinib + albumin-bound paclitaxel, n = 42). The combination of an anti-PD-1 monoclonal antibody with chemotherapy and anti-angiogenic agents demonstrated preliminary efficacy and favorable safety in second-line gastric cancer patients. This study, using real-world data, validates the clinical benefit of this triple regimen, addresses the evidence gap in second-line treatment options, provides new insights for personalized combination strategies in advanced gastric cancer, and holds significant value for guiding clinical practice.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • AiTan (rivoceranib) • albumin-bound paclitaxel
    3d
    Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Tongji Hospital
    New trial
    |
    Jin Beixin (firsekibart)
    8d
    The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights. (PubMed, Front Immunol)
    Future priorities: accelerate late-phase trials for promising regimens, reduce global disparities via regional consortia, integrate precision biomarkers for patient stratification, and translate TME insights into trials. This analysis highlights the need to shift from conventional chemotherapy optimization to precision-driven, globally equitable strategies to improve outcomes for high-risk osteosarcoma patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KDR (Kinase insert domain receptor)
    |
    AiTan (rivoceranib)
    14d
    Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=32, Not yet recruiting, Xiangya Hospital of Central South University
    New trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    15d
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P2 trial
    |
    cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • KC1036
    15d
    Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Peking University People's Hospital
    New P1/2 trial
    |
    AiTan (rivoceranib)
    20d
    Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)
    22d
    DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. (PubMed, J Gastrointest Oncol)
    We hypothesize that the combination of these four therapeutic strategies could significantly enhance treatment efficacy in HER2-positive gastric cancer, particularly in combined positive score (CPS) PD-L1-negative patients. This study was registered at ClinicalTrials.gov (Identifier: NCT06385873).
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • PD-L1 negative • EGFR positive
    |
    AiTan (rivoceranib) • Aidixi (disitamab vedotin) • AiRuiLi (adebrelimab)
    22d
    SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
    23d
    Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=29, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2026
    Trial completion • Trial completion date • Platinum resistant
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    24d
    Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a quantitative systems pharmacology approach. (PubMed, Front Immunol)
    Furthermore, through computer-simulated clinical trials, we find that reducing the dose of apatinib in combination therapy to 125 mg can still achieve therapeutic effects comparable to the original dose. These findings provide valuable insights for future drug development and clinical trial design.
    Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)